DK1819362T3 - Topiske nepafenac-formuleringer - Google Patents

Topiske nepafenac-formuleringer

Info

Publication number: DK1819362T3
Authority: DK; Denmark
Prior art keywords: nepafenac formulations; topical; topical nepafenac; formulations; nepafenac
Prior art date: 2004-12-02

Application number

DK05825662.9T

Other languages

English (en)

Inventor

Warren Wong

Original Assignee

Alcon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-02

Filing date

2005-12-02

Publication date

2010-10-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35848959&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1819362(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-12-02 Application filed by Alcon Inc filed Critical Alcon Inc

2010-10-18 Application granted granted Critical

2010-10-18 Publication of DK1819362T3 publication Critical patent/DK1819362T3/da

Links

238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 title 1
229960001002 nepafenac Drugs 0.000 title 1
230000000699 topical effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Dispersion Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK05825662.9T 2004-12-02 2005-12-02 Topiske nepafenac-formuleringer DK1819362T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US63256204P	2004-12-02	2004-12-02
PCT/US2005/043545 WO2006060618A2 (en)	2004-12-02	2005-12-02	Topical nepafenac formulations

Publications (1)

Publication Number	Publication Date
DK1819362T3 true DK1819362T3 (da)	2010-10-18

Family

ID=35848959

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05825662.9T DK1819362T3 (da)	2004-12-02	2005-12-02	Topiske nepafenac-formuleringer

Country Status (23)

Country	Link
US (3)	US7834059B2 (da)
EP (1)	EP1819362B1 (da)
JP (2)	JP4968844B2 (da)
KR (1)	KR101289661B1 (da)
CN (1)	CN101068573A (da)
AR (1)	AR052252A1 (da)
AT (1)	ATE476200T1 (da)
AU (1)	AU2005311738B2 (da)
BR (1)	BRPI0518904B1 (da)
CA (1)	CA2586807C (da)
CY (1)	CY1110780T1 (da)
DE (1)	DE602005022756D1 (da)
DK (1)	DK1819362T3 (da)
ES (1)	ES2348249T3 (da)
MX (1)	MX2007006558A (da)
PL (1)	PL1819362T3 (da)
PT (1)	PT1819362E (da)
RU (1)	RU2007124638A (da)
SI (1)	SI1819362T1 (da)
TW (1)	TWI358290B (da)
UY (1)	UY29238A1 (da)
WO (1)	WO2006060618A2 (da)
ZA (1)	ZA200704763B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI358290B (en)	2004-12-02	2012-02-21	Alcon Inc	Topical nepafenac formulations
CA2607608A1 (en) *	2005-05-10	2006-11-16	Alcon, Inc.	Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
WO2006121964A2 (en) *	2005-05-10	2006-11-16	Alcon, Inc.	Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
US20090010850A1 (en) *	2007-05-24	2009-01-08	Ousler Iii George W	Formulations and methods for treating dry eye
TW200812575A (en) *	2006-04-28	2008-03-16	Alcon Inc	Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
US20080057022A1 (en) *	2006-08-30	2008-03-06	Erning Xia	Ophthalmic Pharmaceutical Compositions and Uses Thereof
TWI531362B (zh)	2008-07-21	2016-05-01	艾爾康股份有限公司	具有治療劑遞送能力之眼科裝置
TW201023912A (en)	2008-12-05	2010-07-01	Alcon Res Ltd	Pharmaceutical suspension
WO2010101989A1 (en) *	2009-03-03	2010-09-10	Alcon Research, Ltd.	PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CN102340993A (zh) *	2009-03-03	2012-02-01	爱尔康研究有限公司	向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
KR101543613B1 (ko)	2009-12-03	2015-08-11	알콘 리서치, 리미티드	카복시비닐 폴리머를 포함하는 나노입자 현탁액
US9532222B2 (en)	2010-03-03	2016-12-27	Duo Security, Inc.	System and method of notifying mobile devices to complete transactions after additional agent verification
US9544143B2 (en)	2010-03-03	2017-01-10	Duo Security, Inc.	System and method of notifying mobile devices to complete transactions
US9467463B2 (en)	2011-09-02	2016-10-11	Duo Security, Inc.	System and method for assessing vulnerability of a mobile device
EP2790673B1 (en) *	2011-12-16	2017-07-05	Allergan, Inc.	Ophthalmic compositions comprising polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers (soluplus)
WO2014207769A1 (en)	2013-06-27	2014-12-31	Mylan Laboratories Ltd	Process for the preparation of nepafenac
CN104490861A (zh) *	2014-11-21	2015-04-08	三明欣茂药业有限公司	一种缓释型奈帕芬胺眼用制剂
EP3470059B1 (en)	2015-01-26	2020-04-01	Bausch & Lomb Incorporated	Ophthalmic suspension composition
ES2758755T3 (es)	2015-06-01	2020-05-06	Duo Security Inc	Método para aplicar normas de salud de punto final
CN107024550A (zh) *	2016-12-21	2017-08-08	广州仁恒医药科技股份有限公司	奈帕芬胺眼用药物组合物的质控方法
CN106963730A (zh) *	2016-12-22	2017-07-21	广州仁恒医药科技股份有限公司	高度稳定的奈帕芬胺眼用药物组合物
US10412113B2 (en)	2017-12-08	2019-09-10	Duo Security, Inc.	Systems and methods for intelligently configuring computer security
US11658962B2 (en)	2018-12-07	2023-05-23	Cisco Technology, Inc.	Systems and methods of push-based verification of a transaction
IT201900000561A1 (it) *	2019-01-14	2020-07-14	Medivis S R L	Formulazioni topiche oftalmiche chimicamente e fisicamente stabili a base di Nepafenac
JP6994061B2 (ja)	2019-02-15	2022-01-14	ノバルティスアーゲー	４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
CN114272207B (zh) *	2022-01-21	2023-04-11	山东诺明康药物研究院有限公司	一种纳米晶混悬滴眼液及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1226344A (da)	1967-07-31	1971-03-24
CH577461A5 (da)	1975-08-13	1976-07-15	Robins Co Inc A H
US4313949A (en)	1979-09-26	1982-02-02	A. H. Robins Company, Inc.	Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en)	1979-10-18	1981-03-03	A. H. Robins Company, Inc.	3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en)	1980-02-19	1984-09-30	Robins Co Inc A H	2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
US4503073A (en)	1981-01-07	1985-03-05	A. H. Robins Company, Incorporated	2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en)	1981-02-17	1982-03-31	Robins Co Inc A H	2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
US4568695A (en)	1983-12-07	1986-02-04	A. H. Robins Company, Incorporated	2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
US4851443A (en)	1985-03-14	1989-07-25	Smith Kline Dauelsberg, Gmbh	Carboxylic acid amides, compositions and medical use thereof
DE3668450D1 (de)	1985-03-14	1990-03-01	Smithkline Dauelsberg	5-aminosalicylsaeurederivate von nicht-steroidalen entzuendungshemmenden sauren.
US4683242A (en)	1985-10-28	1987-07-28	A. H. Robins Company, Incorporated	Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
DK406686D0 (da)	1986-08-26	1986-08-26	Hans Bundgaard	Carboxylsyrederivater
CA1325382C (en)	1988-01-27	1993-12-21	Takahiro Ogawa	Locally administrable therapeutic composition for inflammatory disease
US5461081A (en)	1989-09-28	1995-10-24	Alcon Laboratories, Inc.	Topical ophthalmic pharmaceutical vehicles
US5521222A (en)	1989-09-28	1996-05-28	Alcon Laboratories, Inc.	Topical ophthalmic pharmaceutical vehicles
US5624893A (en)	1993-10-14	1997-04-29	Alcon Laboratories, Inc.	Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US5475034A (en)	1994-06-06	1995-12-12	Alcon Laboratories, Inc.	Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US6066671A (en) *	1997-12-19	2000-05-23	Alcon Laboratories, Inc.	Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
AR030345A1 (es) *	2000-08-14	2003-08-20	Alcon Inc	Metodo de tratamiento de desordenes relacionados con angiogenesis
AR030346A1 (es) *	2000-08-14	2003-08-20	Alcon Inc	Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
KR20040101499A (ko) *	2002-05-03	2004-12-02	알콘, 인코퍼레이티드	암페낙 또는 네파페낙을 이용한 혈관 내피 성장 인자 매개혈관 장애 치료 방법
US8129431B2 (en)	2003-01-21	2012-03-06	Senju Pharmaceutical Co., Ltd.	Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
TWI358290B (en)	2004-12-02	2012-02-21	Alcon Inc	Topical nepafenac formulations

2005
- 2005-11-23 TW TW094141182A patent/TWI358290B/zh not_active IP Right Cessation
- 2005-11-28 AR ARP050104964A patent/AR052252A1/es not_active Application Discontinuation
- 2005-11-29 UY UY29238A patent/UY29238A1/es not_active Application Discontinuation
- 2005-12-02 WO PCT/US2005/043545 patent/WO2006060618A2/en not_active Ceased
- 2005-12-02 KR KR1020077012413A patent/KR101289661B1/ko not_active Expired - Fee Related
- 2005-12-02 BR BRPI0518904-7A patent/BRPI0518904B1/pt active IP Right Grant
- 2005-12-02 SI SI200531107T patent/SI1819362T1/sl unknown
- 2005-12-02 DK DK05825662.9T patent/DK1819362T3/da active
- 2005-12-02 ZA ZA200704763A patent/ZA200704763B/xx unknown
- 2005-12-02 AU AU2005311738A patent/AU2005311738B2/en not_active Expired
- 2005-12-02 CA CA2586807A patent/CA2586807C/en not_active Expired - Lifetime
- 2005-12-02 ES ES05825662T patent/ES2348249T3/es not_active Expired - Lifetime
- 2005-12-02 CN CNA200580041442XA patent/CN101068573A/zh active Pending
- 2005-12-02 JP JP2007544521A patent/JP4968844B2/ja not_active Expired - Lifetime
- 2005-12-02 EP EP05825662A patent/EP1819362B1/en not_active Expired - Lifetime
- 2005-12-02 MX MX2007006558A patent/MX2007006558A/es active IP Right Grant
- 2005-12-02 AT AT05825662T patent/ATE476200T1/de active
- 2005-12-02 US US11/292,484 patent/US7834059B2/en active Active
- 2005-12-02 PL PL05825662T patent/PL1819362T3/pl unknown
- 2005-12-02 DE DE602005022756T patent/DE602005022756D1/de not_active Expired - Lifetime
- 2005-12-02 RU RU2007124638/15A patent/RU2007124638A/ru unknown
- 2005-12-02 PT PT05825662T patent/PT1819362E/pt unknown
2010
- 2010-09-14 CY CY20101100830T patent/CY1110780T1/el unknown
- 2010-09-23 US US12/888,631 patent/US8071648B2/en not_active Expired - Lifetime
2011
- 2011-10-05 US US13/253,648 patent/US8324281B2/en not_active Expired - Lifetime
- 2011-11-25 JP JP2011257966A patent/JP2012041368A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
PT1819362E (pt)	2010-10-11
US20120029084A1 (en)	2012-02-02
SI1819362T1 (sl)	2010-10-29
EP1819362A2 (en)	2007-08-22
MX2007006558A (es)	2007-06-15
TW200626132A (en)	2006-08-01
AU2005311738B2 (en)	2011-02-03
BRPI0518904A2 (pt)	2008-12-16
DE602005022756D1 (de)	2010-09-16
TWI358290B (en)	2012-02-21
CY1110780T1 (el)	2015-06-10
JP2012041368A (ja)	2012-03-01
HK1104225A1 (en)	2008-01-11
RU2007124638A (ru)	2009-01-10
WO2006060618A3 (en)	2006-10-19
US20060122277A1 (en)	2006-06-08
UY29238A1 (es)	2006-05-31
EP1819362B1 (en)	2010-08-04
AU2005311738A1 (en)	2006-06-08
ES2348249T3 (es)	2010-12-02
KR20070089687A (ko)	2007-08-31
PL1819362T3 (pl)	2010-12-31
CA2586807C (en)	2013-01-29
ATE476200T1 (de)	2010-08-15
US20110015271A1 (en)	2011-01-20
CN101068573A (zh)	2007-11-07
KR101289661B1 (ko)	2013-07-29
ZA200704763B (en)	2008-09-25
BRPI0518904B1 (pt)	2023-01-24
JP2008521926A (ja)	2008-06-26
JP4968844B2 (ja)	2012-07-04
US8071648B2 (en)	2011-12-06
WO2006060618A2 (en)	2006-06-08
US8324281B2 (en)	2012-12-04
CA2586807A1 (en)	2006-06-08
US7834059B2 (en)	2010-11-16
AR052252A1 (es)	2007-03-07

Publication	Publication Date	Title
NL301242I1 (nl)	2023-09-20	ublituximab
ATE476200T1 (de)	2010-08-15	Topische nepafenac-formulierungen
DK1812025T3 (da)	2012-10-22	Stabiliserede bakteriofagformuleringer
DE602005012636D1 (de)	2009-03-19	Erung
DK1750683T3 (da)	2013-04-15	Formuleringer med langvarig frigivelse
DE602005012620D1 (de)	2009-03-19	Spektroskop
DE602005026361D1 (de)	2011-03-31	Make-up Zubereitung
ATE412651T1 (de)	2008-11-15	Pyrrolopyridinderivate
DK1778723T3 (da)	2012-12-03	Il-1-antagonistformuleringer
DK1868586T3 (da)	2013-03-11	Antiinflammatorisk formulering
DK2119472T3 (da)	2014-10-13	Hud-/hårbehandlingssystem
DE502004006772D1 (de)	2008-05-21	Wirkwerkzeug-Barre
DE112005001940A5 (de)	2009-02-26	Skate-Schuh
DE602005001508D1 (de)	2007-08-09	4-amino-5-cyanopyrimidinderivate
DE502005002602D1 (de)	2008-03-13	Fahrzeugtemperiersystem
AT500198B8 (de)	2007-02-15	Ladewagen
DE602005022667D1 (de)	2010-09-16	Haartrockner
AT500249A3 (de)	2006-03-15	Scheibenegge
DE602005003309D1 (de)	2007-12-27	Netzspannungsidentifikator
EP1895843A4 (en)	2010-06-02	TOPICAL MICOGEL FORMULATIONS
SE0601411L (sv)	2006-06-28	Förfarande vid beredning
AT7802U3 (de)	2007-11-15	Parfum-zerstäuber
SE0402638D0 (sv)	2004-10-29	Pharmaceutical use
SE0402678D0 (sv)	2004-11-03	Pharmaceutical use
SE0402639D0 (sv)	2004-10-29	Pharmaceutical use